EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

A Cross-Sectional Seroepidemiological Study on Varicella Zoster Virus in Zhejiang, China

Yingying Yang, Yan Liu, Canjie Zheng, Yao Zhu, Fuxing Chen, Linling Ding, Yu Hu, Xiaohua Qi, Yang Zhou

Vaccines · 21.08.2026 · 14 (8) · 722

DOI: 10.3390/vaccines14080722 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Vaccines, online erschienen am 21.08.2026. Verfasst von Yingying Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunization Program, Hangzhou Center for Disease Control and Prevention (Hangzhou Health Supervision Institution), Hangzhou 310021, Ch…. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Disease Prevention and Control Innovation Team of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study aimed to investigate the levels of varicella antibodies in Zhejiang, China, after a decade of implementing the two-dose varicella vaccine (VarV) strategy.

Methods

Healthy participants aged 1 to 69 years from Zhejiang, China, were recruited from January to April 2024 using multistage stratified random sampling, and varicella zoster virus (VZV) IgG antibodies were detected by ELISA. We assessed the seroprevalence and geometric mean concentration (GMC) of VZV IgG and analyzed related factors using Logistic and linear regression models.

Results

A total of 807 participants were included in the study. The overall seropositivity rate for VZV IgG in the healthy population was 73.08% (95%CI: 69.87–76.11), with a corresponding GMC of 200.97 mIU/mL (95%CI: 182.75 mIU/mL–221.01 mIU/mL). Multivariate analysis identified age group, VarV immunization history, and history of varicella disease as factors significantly associated with both VZV IgG seropositivity and GMC levels (p < 0.05). The seropositivity rate for VZV IgG in children aged 1–14 years was 42.67% (95%CI: 36.22–49.31), with a corresponding GMC of 82.10 mIU/mL (95%CI: 69.14 mIU/mL–97.48 mIU/mL). Furthermore, a significant decline in both seropositivity and GMC was observed over time following vaccination among vaccinated children aged 1–14 years (p < 0.05).

Conclusions

Two-dose VarV vaccination may be considered for inclusion in the national immunization program.

Schlagwörter

Stichwörter der Autor:innen

antibodyseroprevalencevaccinationvaricellavaricella zoster virus

Autor:innen und Institutionen

  • Department of Immunization Program, Hangzhou Center for Disease Control and Prevention (Hangzhou Health Supervision Institution), Hangzhou 310021, China.
  • Department of Immunization Program, Quzhou Center for Disease Control and Prevention (Quzhou Health Supervision Institution), Quzhou 324000, China.
  • Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.

Förderung

  • Disease Prevention and Control Innovation Team of Zhejiang Province

Zitieren

APA

Yang, Y., Liu, Y., Zheng, C., Zhu, Y., Chen, F., Ding, L., Hu, Y., Qi, X., & Zhou, Y. (2026). A Cross-Sectional Seroepidemiological Study on Varicella Zoster Virus in Zhejiang, China. Vaccines, 14(8), 722. https://doi.org/10.3390/vaccines14080722

Vancouver

Yang Y, Liu Y, Zheng C, Zhu Y, Chen F, Ding L, et al. A Cross-Sectional Seroepidemiological Study on Varicella Zoster Virus in Zhejiang, China. Vaccines. 2026;14(8):722. doi:10.3390/vaccines14080722

BibTeX
@article{Yang2026,
  author = {Yang, Yingying and Liu, Yan and Zheng, Canjie and Zhu, Yao and Chen, Fuxing and Ding, Linling and Hu, Yu and Qi, Xiaohua and Zhou, Yang},
  title = {A Cross-Sectional Seroepidemiological Study on Varicella Zoster Virus in Zhejiang, China},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {8},
  pages = {722},
  doi = {10.3390/vaccines14080722}
}
Kostenlos starten →